| (Values in U.S. Thousands) | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 |
| Sales | 8,960 | 43,570 | 47,760 | 32,400 | 23,960 |
| Sales Growth | -79.44% | -8.77% | +47.41% | +35.23% | -14.52% |
| Net Income | -114,660 | -90,610 | -68,060 | -47,250 | -36,250 |
| Net Income Growth | -26.54% | -33.13% | -44.04% | -30.34% | -57.61% |
Affimed N.V. (AFMD)
0.7850 x 5 0.8500 x 8
Post-market by (Cboe BZX)
0.7811 -0.0239 (-2.97%) 03/28/25 [NASDAQ]
0.7850 x 5 0.8500 x 8
Post-market 0.7811 unch (unch) 16:00 ET
for Fri, Mar 28th, 2025
Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany.
Fiscal Year End Date: 12/31